Next 10 |
2024-04-14 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-08 12:00:03 ET Irene Buhalo from Jefferies issued a price target of $40.00 for SUPN on 2024-04-08 10:10:00. The adjusted price target was set to $40.00. At the time of the announcement, SUPN was trading at $32.265. SUPN currently trades -16.55% versus its 52 week...
2024-04-08 08:39:34 ET Supernus Pharmaceuticals ( NASDAQ: SUPN ) shares dipped ~11% premarket on Monday after the U.S. drug regulator rejected its experimental apomorphine infusion device for the continuous treatment of motor fluctuations associated with Parkinson’s d...
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is ...
2024-04-05 01:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-15 22:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Super...
Fourth quarter 2023 net sales of Qelbree ® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year 2022. Fourth quarter 2023 net sales of GOCOVRI ® increased 10% to $32.0 milli...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-16 11:10:43 ET More on iShares Russell 2000 ETF: IWM: Technical Analysis Says You Should Buy Small Caps IWM: Supply-Side Disinflation Benefits Small Caps The Most Small-Cap ETFs: Performance, Fundamentals, And Rankings For 102 Funds Investors retract ...
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
2024-04-14 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion...
2024-04-08 12:00:03 ET Irene Buhalo from Jefferies issued a price target of $40.00 for SUPN on 2024-04-08 10:10:00. The adjusted price target was set to $40.00. At the time of the announcement, SUPN was trading at $32.265. SUPN currently trades -16.55% versus its 52 week...